Core Viewpoint - The company, Hualan Biological Engineering Inc., has announced its 2025 semi-annual profit distribution plan, which includes a cash dividend of 6.00 RMB per 10 shares for shareholders, totaling approximately 357 million RMB [3][7]. Group 1: Profit Distribution Details - The total share capital of the company is 601,027,500 shares, with 6,027,467 shares repurchased and excluded from the profit distribution calculation, resulting in a base of 595,000,033 shares for the dividend distribution [2][3]. - The cash dividend per share, after tax, is calculated as 0.5939828 RMB, with a total cash distribution amounting to 357,000,019.80 RMB [2][3]. - The dividend distribution will not include stock bonuses or capital reserves, and any undistributed profits will be carried forward to future periods [3][7]. Group 2: Key Dates - The record date for the dividend distribution is set for October 24, 2025, while the ex-dividend date is October 27, 2025 [8][9]. Group 3: Dividend Payment Method - Cash dividends will be directly credited to the shareholders' accounts through their respective securities companies on the ex-dividend date [10]. - The company will bear all legal responsibilities if there are any discrepancies in the cash dividends due to changes in the number of shares held by shareholders during the distribution application period [11]. Group 4: Adjustments Related to Shareholding - The minimum selling price for shares held by major shareholders and executives will be adjusted according to the profit distribution plan, ensuring it does not fall below the adjusted issue price [12][13].

Group 1 - The core point of the article is that Hualan Vaccine announced a cash dividend distribution plan for the first half of 2025, proposing to distribute 6 RMB per 10 shares to all shareholders [1] - The record date for the dividend distribution is set for October 24, 2025, and the ex-dividend date is October 27, 2025 [1]

证券代码：301207 证券简称：华兰疫苗 公告编号：2025-044 华兰生物疫苗股份有限公司 2025年半年度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、公司目前通过回购专用账户持有本公司股份 6,027,467 股，根据《公司法》 的规定，该部分已回购的股份不享有参与本次利润分配的权利。 2、本次权益分派实施后，按公司总股本折算每股现金红利计算如下：按公司 总股本（含回购股份）折算的每股现金分红（含税）=本次实际现金分红总额/公司 总股本=357,000,019.80 元/601,027,500 股=0.5939828 元/股【注】，按公司总股本折 算的每 10 股现金红利为 5.939828 元。 3、本次权益分派实施后除权除息参考价=（除权除息日前一日收盘价-按公司 总股本折算的每股现金红利）=除权除息日前一日收盘价-0.5939828 元/股。 【注：根据相关要求，此项数据保留七位小数，最后一位直接截取，不四舍五 入。】 权的股本总数发生变动，则以实施分配方案时股权登记日的享有利润分配权的股本 总数为基数，按照 ...

Core Points - The Shanghai Composite Index closed at 3877.20 points, above the annual line, with a decline of 1.00% [1] - The total trading volume of A-shares reached 1,188.96 billion yuan [1] - A total of 22 A-shares have surpassed the annual line, with notable stocks showing significant deviation rates [1] Summary of Key Stocks - Hualan Vaccine (301207) had a price increase of 8.85% and a deviation rate of 8.88% [1] - Zhujiang Piano (002678) rose by 10.11% with a deviation rate of 8.54% [1] - Shiroyama Real Estate (002016) increased by 3.09% and had a deviation rate of 2.87% [1] - Other stocks with notable performance include Weijie Chuangxin (688153) with a 3.19% increase and a deviation rate of 2.65% [1] - The stocks with the smallest deviation rates include Guangdong Wannianqing (301111) and Longjiang Transportation (601188), both just above the annual line [2]

Market Overview - The Shanghai Composite Index is at 3916.86 points, above the annual line, with a change of 0.12% [1] - The total trading volume of A-shares is 909.4 billion yuan [1] Stocks Breaking Annual Line - A total of 20 A-shares have surpassed the annual line today, with notable stocks including: - Shenglong Co., Ltd. (603178) with a deviation rate of 9.96% - Lege Co., Ltd. (300729) with a deviation rate of 2.14% - Jinguang Co., Ltd. (300510) with a deviation rate of 1.75% [1] Deviation Rate Rankings - The following stocks have the highest deviation rates after breaking the annual line: - Shenglong Co., Ltd. (603178): Today's change of 10.00%, turnover rate of 4.72%, latest price at 21.45 yuan [1] - Lege Co., Ltd. (300729): Today's change of 4.01%, turnover rate of 4.10%, latest price at 15.58 yuan [1] - Jinguang Co., Ltd. (300510): Today's change of 2.00%, turnover rate of 5.62%, latest price at 4.60 yuan [1] Stocks with Smaller Deviation Rates - Stocks with smaller deviation rates that have just crossed the annual line include: - Changjiang Electric Power (600900): Today's change of 0.36%, latest price at 28.03 yuan, deviation rate of 0.01% [2] - Beiqi Blue Valley (600733): Today's change of 3.05%, latest price at 8.11 yuan, deviation rate of 0.03% [2] - Hongcheng Environment (600461): Today's change of 0.22%, latest price at 9.10 yuan, deviation rate of 0.05% [2]

Market Overview - The biopharmaceutical sector experienced a decline of 1.58% on October 14, with Aopumai leading the drop [1] - The Shanghai Composite Index closed at 3865.23, down 0.62%, while the Shenzhen Component Index closed at 12895.11, down 2.54% [1] Stock Performance - Notable gainers in the biopharmaceutical sector included: - Iwo Biotech (300357) with a closing price of 30.21, up 4.79% on a trading volume of 149,900 shares and a turnover of 448 million yuan [1] - Kain Technology (688687) closed at 28.91, up 4.14% with a trading volume of 127,000 shares and a turnover of 369 million yuan [1] - Major decliners included: - Aopumai (688293) which closed at 56.09, down 7.20% with a trading volume of 18,200 shares and a turnover of 106 million yuan [2] - Olin Biotech (688319) closed at 23.95, down 7.06% with a trading volume of 65,500 shares and a turnover of 162 million yuan [2] Capital Flow - The biopharmaceutical sector saw a net outflow of 503 million yuan from institutional investors, while retail investors contributed a net inflow of 329 million yuan [2] - The capital flow for specific stocks showed: - Iwo Biotech (300357) had a net outflow of 43.35 million yuan from institutional investors [3] - Kain Technology (688687) experienced a net inflow of 8.78 million yuan from institutional investors [3]

Core Insights - The company Hualan Vaccine (301207) reported that as of September 30, 2025, it has over 17,000 shareholders [1] Company Summary - Hualan Vaccine has a significant shareholder base, indicating a broad interest in the company's stock [1]

Core Viewpoint - The company held its second extraordinary general meeting of shareholders in 2025, where all proposed resolutions were approved without any objections [1][2]. Meeting Details - The meeting took place on September 22, 2025, at 13:30, with both on-site and online voting options available [3][4]. - The total number of shares with voting rights was 595,000,033 [5]. - A total of 152 shareholders participated, representing 487,150,449 shares, which is 81.8740% of the total voting shares [6]. Shareholder Participation - Among the participating shareholders, 150 were small shareholders, representing 28,150,449 shares, or 4.7312% of the total voting shares [7]. - The meeting was presided over by the chairman, Mr. An Kang, and was witnessed by lawyers from Anhui Chengyi Law Firm, who provided a legal opinion confirming the meeting's compliance with regulations [7][8]. Voting Results - The proposal regarding the 2025 mid-term profit distribution plan was approved with 486,923,499 votes in favor, accounting for 99.9534% of the valid votes cast [8]. - Small shareholders voted 27,923,499 shares in favor, representing 99.1938% of the small shareholders' valid votes [8]. Legal Opinion - The legal advisors confirmed that the meeting's procedures, participant qualifications, proposals, voting processes, and results were all in accordance with legal and regulatory requirements [8]. Documents for Reference - The resolutions from the second extraordinary general meeting and the legal opinion from Anhui Chengyi Law Firm are available for review [9].

华兰生物疫苗股份有限公司 2025年第二次临时股东会决议公告 证券代码：301207 证券简称：华兰疫苗 公告编号：2025-043 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 1.本次股东会未出现否决议案的情形。 2.本次股东会不涉及变更以往股东会已通过的决议。 一、会议召开和出席情况 1、本次股东会的召开时间： 现场会议召开时间为：2025 年 9 月 22 日下午 13:30 网络投票时间：2025 年 9 月 22 日。其中通过深圳证券交易所交易系统进行 网络投票的具体时间为 2025 年 9 月 22 日上午 9:15—9:25,9:30—11:30 和下午 13:00—15:00；通过深圳证券交易所互联网投票的具体时间为 2025 年 9 月 22 日 9:15 至 15:00 期间的任意时间。 2、会议召开地点：华兰生物疫苗股份有限公司（以下简称"公司"）办公楼 会议室 3、召集人：公司董事会 4、会议方式：现场投票、网络投票相结合的方式 通过现场和网络投票的股东 152 人，代表股份 487,150,449 股，占公司有表 决权 ...

关于 华兰生物疫苗股份有限公司 召开 2025 年第二次临时股东会的 法律意见书 安徽承义律师事务所 安徽承义律师事务所 中国.合肥市政务区怀宁路 200 号栢悦中心 5 楼 邮编: 230022 电话（Tel）: （86-551）65609815 传真（Fax）: （86-551）65608051 网址（Website）: www.chengyi-law.com 电子信箱（E-mail）：chengyilawyer@163.com 安徽承义律师事务所 关于华兰生物疫苗股份有限公司 一、本次股东会召集人资格和召集、召开的程序 经核查，本次股东会是由公司第二届董事会召集，公司已于 2025 年 8 月 28 日在中国证监会指定的信息披露网站和深圳证券交易所网站上披露了《关于召开 2025 年第二次临时股东会的通知》。本次股东会的现场会议于 2025 年 9 月 22 日 13:30 在河南省新乡市华兰大道甲 1 号附 1 号公司办公楼会议室如期召开。 本次股东会的召集人资格和召集、召开程序符合法律、法规、规范性文件和 公司章程的规定。 二、本次股东会出席人员的资格 经核查，出席会议的公司股东及股东代表 152 ...